Smart Patients Get Smart Care™

The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients

Response to Vaccination in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

In science and medicine, information is constantly changing and may become out-of-date as new data emerge. All articles and interviews are informational only, should never be considered medical advice, and should never be acted on without review with your health care team.

Dr. Susan Leclair has reviewed three abstracts from the 2021 American Society of Hematology Annual Meeting and Exposition, or ASH 2021, on chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL / SLL) patients’ responses to vaccines, two on the COVID-19 vaccine, and one on the shingles vaccines. These trials include data on both antibodies (humeral) and T cell (cellular) responses. We suggest reading all three articles together as Dr. Leclair explains some of the nuances of the impairment of immunity in CLL / SLL in her discussion across all three articles.

ASH 2021: Effect of Bruton Tyrosine Kinase Inhibitor on Serologic and Cellular Immune Responses to Recombinant Herpes Zoster Vaccine

ASH 2021: Humoral (Antibody) and Cellular Immunogenicity of COVID-19 Vaccinations in Patients with CLL

ASH 2021: Antibody and T-Cell Responses to Covid-19 mRNA Vaccines in Patients with B-Cell Lymphomas and Chronic Lymphocytic Leukemia (CLL)